Previous 10 | Next 10 |
Shares of MeiraGTx Holdings (NASDAQ:MGTX) -- a clinical-stage biotech company -- are down by 11.51% as of 11:55 a.m. EST on Thursday, following the company's announcement of the pricing of a public offering of common stock. Investors aren't thrilled with the prospect of MeiraGTx dil...
Gainers: Naked Brand (NAKD) +116%.Phoenix New Media (FENG) +48%.Titan Pharmaceuticals (TTNP) +36%.HighPoint Resources (HPR) +32%.Arcimoto (FUV) +32%.Ayro (AYRO) +29%.CIIG Merger (CIIC) +27%.Aptevo Therapeutics (APVO) +27%.Sonos (SONO) +27%.Blink Charging (BLNK) +23%.Losers: Ebang In...
Gainers: Medigus (MDGS) +30%, Aptevo Therapeutics (APVO) +29%, Corcept Therapeutics (CORT) +23%, Opiant Pharmaceuticals (OPNT) +15%, Aquestive Therapeutics (AQST) +11%.Losers: MeiraGTx Holdings (MGTX) -11%, Kintara Therapeutics (KTRA) -10%,...
X Financial (XYF) -33%.MeiraGTx Holdings (MGTX) -10% on public offering pricing at $12.85/share.Tantech Holdings (TANH) -9%.BeyondSpring (BYSI) -9% on public offering pricing at $10.0/share.Chindata Group Holdings (CD) -7% on Q3 earnings release.Phoenix Tree Hold...
MeiraGTx (MGTX) slips 10% in premarket, after pricing its previously announced public offering of 5M shares at $12.85/share, for gross proceeds of ~$64.3M.Offer price represents discount of ~11% over last close price of $14.36.The offering is expected to close by November 23. For ...
MeiraGTx (MGTX) -2.2% AH, commenced an underwritten public offering of 5M shares; underwriters granted 30-day option to purchase up to an additional 750K shares.Offer terms and size have not yet been disclosed.Proceeds to be used for general corporate purposes, including working cap...
MeiraGTx ([[MGTX]] +2.5%) has announced 12-month data from the ongoing Phase 1/2 trial of AAV-RPGR, an investigational gene therapy for the treatment of X-linked retinitis pigmentosa ((XLRP)). Data were presented at the American Academy of Ophthalmology.The primary endpoint of the trial is sa...
LONDON and NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced 12-month data from the ongoing Phase 1/2 clinical trial ( NCT03252847 ) of AAV-RPGR, an investigational gene th...
LONDON and NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the Barcl...
MeiraGTx (MGTX): Q3 GAAP EPS of -$0.17 beats by $0.52.Revenue of $5.1M (+42.5% Y/Y) beats by $4.19M.Press Release For further details see: MeiraGTx EPS beats by $0.52, beats on revenue
News, Short Squeeze, Breakout and More Instantly...
MeiraGTx Holdings plc Company Name:
MGTX Stock Symbol:
NASDAQ Market:
MeiraGTx Holdings plc Website:
- Positive data from the Phase 1 AQUAx study in radiation-induced xerostomia (RIX) presented in an oral session at the American Academy of Oral Medicine 2024 annual meeting (AAOM) April 17-20, 2024 - Received $50 million milestone following initiation of the extension study for the Ph...
LONDON and NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company gave an oral presentation at the American Academy of Oral Medicine Annual Conference, being held f...
2024-04-17 00:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...